Neumirna Therapeutics ApS: Financial statements 2025
CVR: 41696451
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Neumirna Therapeutics ApS (CVR 41696451) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -53,859,865 and a net result of DKK -55,785,767 compared with DKK -6,954,201 the year before. Equity in the 2025 report amounted to DKK 91,816,175. The solvency ratio was 91.5%. The company had 10 employees in the financial year.
- Gross Profit
- DKK -53,859,865
- Profit/Loss
- DKK -55,785,767
- Equity
- DKK 91,816,175
- Total Assets
- DKK 100,357,397
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -53.9M | -55.8M | 91.8M | 10 |
| 2024 | - | -5.5M | -7M | -18.4M | 5 |
| 2023 | - | -5.5M | -8M | -11.5M | 3 |
| 2022 | - | -4.7M | -5.3M | -3.4M | 3 |
Official annual report
How creditworthy is Neumirna Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of September 15, 2025, Ellen Kinson Donnelly has joined the board of directors of Neumirna Therapeutics ApS.
As of September 15, 2025, Ellen Kinson Donnelly is registered as adm. dir. of Neumirna Therapeutics ApS.
As of September 15, 2025, Janine Terra Erler has stepped down as adm. dir. of Neumirna Therapeutics ApS.
As of August 11, 2025, is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 10%.
As of August 11, 2025, is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 15%.
Neumirna Therapeutics ApS has published its annual report for 2024. Gross profit came to DKK -5,495,935, and the net result was DKK -6,954,201.
As of June 27, 2025, EY Godkendt Revisionspartnerselskab has been appointed auditor of Neumirna Therapeutics ApS.
As of June 27, 2025, Beierholm Godkendt Revisionspartnerselskab has stepped down as auditor of Neumirna Therapeutics ApS.
As of May 15, 2025, HELLERUNG ApS is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 25%.
As of May 15, 2025, is registered as an owner of Neumirna Therapeutics ApS with an ownership share of 15%.
About Neumirna Therapeutics ApS
Neumirna Therapeutics ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Ellen Kinson Donnelly. The board consists of Luis Garcia Pareras (chair), Andreas Wallnöfer, Ellen Kinson Donnelly and Francesco Paolo Di Giorgio. The company's owners include HELLERUNG ApS, INVIVO VENTURES III, FCRE and Innovestor Life Science Fund Ky. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK -53,859,865 and a net result of DKK -55,785,767 compared with DKK -6,954,201 the year before. Equity in the 2025 report amounted to DKK 91,816,175.